Effect of a short-term and long-term melatonin administration on mammary carcinogenesis in female Sprague-Dawley rats influenced by repeated psychoemotional stress

Acta Veterinaria Brno

Volumn 76, Issue 3, 2007, Pages 371-377

  Kassayova M ^a   Adamekova E ^b   Bojkova B ^a   Kubatka, P ^c   Ahlers, I ^a   Ahlersova E ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b ABBOTT LABORATORIES   (United States)

^c Jessenius Faculty of Medicine in Martin and University Hospital Martin   (Slovakia)

Author keywords

Mammary carcinogenesis; Melatonin; Psychoemotional stress restraint; Rat

Indexed keywords

ANIMALIA; RATTUS;

EID: 42449127579     PISSN: 00017213     EISSN: None     Source Type: Journal    
DOI: 10.2754/avb200776030371     Document Type: Article

References (37)

1. ADÁMEKOVÁ E, MARKOVÁ M, KUBATKA P, BOJKOVÁ B, AHLERS I, AHLERSOVÁ E 2003: NMU-induced mammary carcinogenesis in female rats is influenced by repeated psychoemotional stress. Neoplasma 50: 428-432
2. AHLERS I, AHLERSOVÁ E, HALÁTOVÁ K, ŠMAJDA B, TOROPILA M 1990: The circadian and circa-annual reponse of rat serum corticosterone to different stressors. Physiol Bohemoslov 39: 371-378
3. AHLERSOVÁ E, AHLERS I, KUBATKA P, BOJKOVÁ B, MÔCIKOVÁ K, GAJDOŠOVÁ Š, ONDERKOVÁ HM 2000: Melatonin and retinyl acetate as chemopreventives in DMBA-induced mammary carcinogenesis in female Sprague-Dawley rats. Folia Biol Prague 46: 69-72
4. ANISIMOV VN 2003: The role of pineal gland in breast cancer development. Crit Rev Oncol Hematol 46: 221-234
5. BEN-ELIYAHU S, SHAKHAR G 2001: The impact of stress, catecholamines, and the menstrual cycle on NK activity and tumour development: from in vitro studies to biological significance. In: ADER R, FELTEN DL, COHEN N (Eds.): Psychoneuroimmunology, vol. 2. Academic Press, New York, pp. 545-563
6. BLASK DE, DAUCHY RT, SAUER LA, KRAUSE JA 2004: Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumour linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 25: 951-960
7. BLASK DE, HILL SM 1986: Effects of melatonin on cancer: Studies on MCF-7 human breast cancer cells in culture. J Neural Transm 21(Suppl): 433-449
8. BLASK DE, SAUER LA, DAUCHY RT, HOLOWACHUK EW, RUHOFF MS, KOPFF HS 1999: Melatonin inhibition of cancer growth in vivo involves supression of tumour fatty acid metabolism via melatonin receptor-mediated signal transduction events. Cancer Res 59: 4693-4701
9. BOJKOVÁ B, KUBATKA P, MÔCIKOVÁ K, MNÍCHOVÁ M, AHLERSOVÁ E, AHLERS I 2000: Effects of retinyl acetate and melatonin on N-methyl-N-nitrosourea - induced mammary carcinogenesis in rats. Preliminary report. Folia Biol Prague 46: 73-76
10. CARRILLO-VICO A, GUERRERO JM, LARDONE PJ, REITER RJ 2005: A review of the multiple actions of melatonin on the immune system. Endocrine 27: 189-200
11. COS S, FERNÁNDEZ F, SÁNCHEZ-BARCELÓ EJ 1996b: Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci 58: 2447-2453
12. COS S, GONZÁLEZ A, GÜEZMES A, MEDIAVILLA MD, MARTÍNEZ-CAMPA C, ALONSO-GONZÁLEZ C, SÁNCHEZ-BARCELÓ EJ 2006: Melatonin inhibits the growth of DMBA-induced mammary tumours by decreasing the local biosynthesis of estrogens through the modulation of aromatase activity. Int J Cancer 118: 274-278
13. COS S, MARTÍNEZ-CAMPA C, MEDIAVILLA MD, SÁNCHEZ- BARCELÓ EJ 2005: Melatonin modulates aromatase activity in MCF-7 human breast cancer cells. J Pineal Res 38: 136-142
14. COS S, RECIO J, SÁNCHEZ-BARCELÓ EJ 1996a: Modulation of the lenght of the cell cycle time of MCF-7 human breast cancer cells by melatonin. Life Sci 58: 811-816
15. GARCIA RATO A, GARCIA PEDRERO JM, MARTINEZ MA, DEL RIO B, LAZO PS, RAMOS S 1999: Melatonin blocks the activation of estrogen receptor for DNA binding. FASEB J 13: 857-868
16. KAVETSKY RE, TURKEVICH NM, BALITSKY KP 1966: On the psychophysiological mechanism of the organism's resistance to tumour growth. Ann NY Acad Sci 125: 933-945
17. KUBATKA P, BOJKOVÁ B, MÔCIKOVÁ-KALICKÁ K, MNÍCHOVÁ-CHAMILOVÁ M, ADÁMEKOVÁ E, AHLERS I, AHLERSOVÁ E, ČERMÁKOVÁ M 2001: Effects of tamoxifen and melatonin on mammary gland cancer induced by N-methyl-N-nitrosourea and by 7,12-dimethylbenz[a]anthracene, respectively, in female Sprague-Dawley rats. Folia Biol Prague 47: 5-10
18. KUBATKA P, AHLERSOVÁ E, AHLERS I, BOJKOVÁ B, KALICKÁ K, ADÁMEKOVÁ E, MARKOVÁ M, CHAMILOVÁ M, ČERMÁKOVÁ M 2002: Variability of mammary carcinogenesis induction in female Sprague-Dawley and Wistar:Han rats: the effect of season and age. Physiol Res 51: 633-640
19. LENOIR V, DE JONAGE-CANONICO MBY, PERRIN MH, MARTIN A, SCHOLLER R, KERDELHUE B 2005: Preventive and curative effect of melatonin on mammary carcinogenesis induced by dimethylbenz[a] ant hracene in the female Sprague-Dawley rat. Breast Cancer Res 7: CDLXX-CDLXXVI
20. LEON-BLANCO MM, GUERRERO JM, REITER RJ, CALVO JR, POZO D 2003: Melatonin inhibits telomerase activity in the MCF-7 tumour cell line both in vivo and in vitro. J Pineal Res 35: 204-211
21. MAESTRONI GJM. 2001: The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 10: 467-476
22. MEDIAVILLA MD, COS S, SÁNCHEZ-BARCELÓ EJ 1999: Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci 65: 415-420
23. MEYER L, CASTON J, MENSAH-NYAGAN AG 2006: Seasonal variation of the impact of a stressful procedure on open field behaviour and blood corticosterone in laboratory mice. Behav Brain Res 167: 342-348
24. MILLER WR 2004: Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Behav Endocrinol Metab 18: 1-32
25. MOYNIHAN JA 2003: Mechanisms of stress-induced modulation of immunity. Brain Behav Immun 17: S11-S16
26. NEWBERRY BH, FRANKIE G, BEATTY PA, MALONEY BD, GILCHRIST JC 1972: Shock stress and DMBA-induced mammary tumours. Psychosom Med 34: 295-303
27. NEWBERRY BH, GILDOW J, WOGAN J, REESE RL 1976: Inhibition of Huggins tumours by forced restraint. Psychosom Med 38: 155-162
28. REITER RJ, TAN DX, OSUNA C, GITTO E 2000: Actions of melatonin in the reduction of oxidative stress: a review. J Biomed Sci 7: 444-458
29. REITER RJ, TAN DX, SAINZ RM, MAYO JC, LOPEZ-BURILLO S 2002: Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 54: 1299-1321
30. SAEZ MC, BARRIGA C, GARCIA JJ, RODRIGUEZ AB, ORTEGA E 2005a: Effect of the preventive-therapeutic administration of melatonin on mammary tumour-bearing animals. Mol Cell Biochem 268: 25-31
31. SAEZ MC, BARRIGA C, GARCIA JJ, RODRIGUEZ AB, MASOT J, DURAN E, ORTEGA E 2005b: Melatonin increases the survival time of animals with untreated mammary tumours: Neuroendocrine stabilization. Mol Cell Biochem 278: 15-20
32. SÁNCHEZ-BARCELÓ EJ, COS S, FERNÁNDEZ R, MEDIAVILLA MD 2003: Melatonin and mammary cancer: a short review. Endocr Relat Cancer 10: 153-159
33. SÁNCHEZ-BARCELÓ EJ, COS S, MEDIAVILLA D, MARTÍNEZ-CAMPA C, GONZÁLEZ A, ALONSO-GONZÁLEZ C 2005: Melatonin-estrogen interactions in breast cancer. J Pineal Res 38: 217-222
34. TAMARKIN L, COHEN M, ROSELLE D, REICHERT C, LIPPMAN M, CHABNER B 1981: Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a) anthracene - induced mammary tumours in the rat. Cancer Res 41: 4432-4436
35. TEJWANI GA, GUDEHITHLU KP, HANISSIAN SH, GIENAPP IE, WHITACRE CC, MALARKEY WB 1991: Facilitation of dimethylbenz[a]anthracene-induced rat mammary tumourigenesis by restraint stress: Role of beta-endorphin, prolactin and naltrexone. Carcinogenesis 12: 637-641
36. TYCZYNSKI JE, PLESKO I, AARELEID T, PRIMIC-ZAKELJ M, DALMAS M, KURINAITIS J, STENGREVICS A, PARKIN DM 2004: Breast cancer mortality patterns and time trends in 10 new EU member states: Mortality declining in young women, but still increasing in the erderly. Int J Cancer 112: 1056-1064
37. ZELENA D, MERGL Z, FÖLDES A, KOVÁCS KJ, TÓTH Z, MAKARA GB 2003: Role of hypothalamic inputs in maintaining pituitary-adrenal responsiveness in repeated restraint. Am J Physiol Endocrinol Metab 285: E1110-E1117